Publication:
Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health

dc.contributor.authorBanerjee, Yajnavalka
dc.date.accessioned2023-04-25T09:31:44Z
dc.date.available2023-04-25T09:31:44Z
dc.date.issued2022
dc.description.abstractAbstract: Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as “Cardiometabolic Disease” (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.en_US
dc.identifier.other204-2022.134
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/1182
dc.language.isoenen_US
dc.subjectCOVIDen_US
dc.subjectMolecularen_US
dc.subjectInflammationen_US
dc.subjectDiabetesen_US
dc.subjectCardiometabolicen_US
dc.titleMolecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic healthen_US
dc.typeArticleen_US
dspace.entity.typePublicationen_US

Files